MICROVISION INC (MVIS)

Sector: Information Technology

    Home/Companies/MVIS/Annual Meeting

2026 Annual Meeting Analysis

MICROVISION INC · Meeting: July 10, 2026

Policy v1.2medium confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

4

Directors AGAINST

3

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Directors

4 FOR/3 AGAINST

Against Analysis

✗ AGAINST
Simon Biddiscombe3-year TSR underperformance vs XLK ETF fallback: MVIS 3-year return -95.3% vs XLK, absolute TSR negative triggering 30pp threshold; director tenure since 2018 covers full underperformance period; no named peer group disclosed for director TSR benchmark purposes; 5-year TSR also deeply negative (-98.3%) confirming sustained underperformance

Mr. Biddiscombe has served since 2018 and the stock has declined approximately 95% over three years and 98% over five years, deeply exceeding the 30-percentage-point underperformance threshold that applies under the ETF fallback benchmark (XLK) for companies with negative absolute three-year returns; the five-year record does not provide a mitigant because underperformance is sustained across both periods.

✗ AGAINST
Robert P. Carlile3-year TSR underperformance vs XLK ETF fallback: MVIS 3-year return -95.3%, absolute TSR negative triggering 30pp threshold; director tenure since 2017 covers full underperformance period; 5-year TSR also deeply negative (-98.3%) confirming sustained underperformance

Mr. Carlile has served as a director since 2017 and as Board Chair since 2022; with MVIS down approximately 95% over three years and 98% over five years against the XLK benchmark, the underperformance far exceeds the applicable 30-percentage-point threshold, and the five-year record provides no mitigant given the sustained nature of the decline.

✗ AGAINST
Jeffrey A. Herbst3-year TSR underperformance vs XLK ETF fallback: MVIS 3-year return -95.3%, absolute TSR negative triggering 30pp threshold; director tenure since 2022 covers the majority of the underperformance period; 5-year TSR -98.3% confirms sustained underperformance

Mr. Herbst has served since 2022 and his tenure covers well over 24 months of the three-year underperformance window; the stock's approximately 95% three-year decline far exceeds the 30-percentage-point ETF fallback threshold applicable to companies with negative absolute returns, and the five-year record is similarly deeply negative with no mitigant.

For Analysis

✓ FOR
Glen W. DeVosDirector since 2025 — within 24-month new director exemption

Mr. DeVos joined the board in 2025 and is exempt from the TSR underperformance trigger under the policy's 24-month new director exemption; as the newly appointed CEO he has not had a reasonable opportunity to influence the board's long-term performance record.

✓ FOR
Laura J. PetersonDirector since July 2025 — within 24-month new director exemption

Ms. Peterson joined the board in July 2025, well within the 24-month new director exemption, so the TSR underperformance trigger does not apply to her; she has not had a reasonable opportunity to contribute to a turnaround.

✓ FOR
Peter SchabertDirector since 2024 — tenure covers less than half the 3-year underperformance period; flagged but not automatic AGAINST

Mr. Schabert joined in 2024 and has served for less than two years, meaning his tenure covers less than half of the three-year underperformance period; under the policy this is flagged but does not automatically result in a AGAINST vote, and the policy gives newer directors time to contribute before being held accountable for prior-period performance.

✓ FOR
Jada M. SmithDirector since 2024 — tenure covers less than half the 3-year underperformance period; flagged but not automatic AGAINST

Ms. Smith joined in 2024 and has served for less than two years, covering less than half of the three-year underperformance window; consistent with policy, this is flagged as context but does not automatically trigger a AGAINST vote given her limited tenure.

The board presents seven nominees. Three long-tenured directors (Biddiscombe since 2018, Carlile since 2017, Herbst since 2022) receive AGAINST votes because MVIS's approximately 95% three-year price decline and approximately 98% five-year decline far exceed the ETF fallback underperformance threshold (XLK; 30 percentage points for companies with negative absolute three-year returns), and the five-year record provides no mitigant. Two very new directors (DeVos and Peterson, both 2025) are exempt under the 24-month new director rule. Two directors added in 2024 (Schabert and Smith) are flagged but receive FOR votes because their tenure covers less than half the underperformance period.

Say on Pay

✗ AGAINST

CEO

Glen DeVos

Total Comp

$3,387,845

Prior Support

N/A

Pay-for-performance misalignment: MVIS 3-year TSR -95.3% while CEO received $3,387,845 total compensationCEO stock award ($3,033,795) represents approximately 90% of total pay — equity-heavy but vests on time/service schedule without disclosed performance conditions for the inducement grant portionIncentive plan metrics (revenue at $10M threshold, cash opex) are short-term and modest given company stage; no long-term TSR or ROIC hurdles for the primary equity grantCompany lost approximately $95 million in 2025 with stock down approximately 68% in the past year

While CEO Glen DeVos only joined in late 2025 and his $3.39 million total compensation package is largely composed of equity (approximately 90% in stock awards), the primary equity grant of 1,300,000 RSUs awarded as an inducement vests purely on a time/service schedule over four years with no performance conditions attached — meaning the largest single component of pay is effectively fixed compensation disguised as variable pay regardless of shareholder outcomes. The company lost approximately $95 million in 2025, the stock declined approximately 95% over three years, and the short-term bonus plan's performance hurdles (at least $10 million in revenue, no more than $55 million in cash operating expenses) are modest relative to the company's scale of losses and do not include any long-term stock price or return targets that would meaningfully tie executive outcomes to the shareholder experience. This combination of a large time-vesting-only equity grant alongside a pattern of deep value destruction represents a pay-for-performance failure that warrants a AGAINST vote.

Auditor Ratification

✓ FOR

Auditor

Baker Tilly US, LLP

Tenure

N/A

Audit Fees

$673,020

Non-Audit Fees

$122,585

Non-audit fees (audit-related fees of $82,700 plus tax fees of $39,885, totaling approximately $122,585) represent about 18% of audit fees of $673,020, well below the 50% threshold that would raise independence concerns; auditor tenure is not explicitly disclosed so the tenure trigger cannot fire; and Baker Tilly is a large national firm appropriate for a sub-$1B company.

Overall Assessment

The 2026 MicroVision annual meeting presents five proposals across a company in significant financial distress, with the stock down approximately 95% over three years and facing Nasdaq delisting risk. The most consequential governance concerns are the three long-tenured directors who oversaw the period of deep value destruction (AGAINST votes for Biddiscombe, Carlile, and Herbst) and an executive compensation program where the CEO's largest equity award vests purely on time with no performance conditions, creating a pay-for-performance disconnect despite the company's severe losses.

Filing date: June 11, 2026·Policy v1.2·medium confidence